KR102736851B1 - 글루코코르티코이드의 생체내 투여에 의해 매개된 약역학적 반응을 모니터링하는 방법 - Google Patents

글루코코르티코이드의 생체내 투여에 의해 매개된 약역학적 반응을 모니터링하는 방법 Download PDF

Info

Publication number
KR102736851B1
KR102736851B1 KR1020207008663A KR20207008663A KR102736851B1 KR 102736851 B1 KR102736851 B1 KR 102736851B1 KR 1020207008663 A KR1020207008663 A KR 1020207008663A KR 20207008663 A KR20207008663 A KR 20207008663A KR 102736851 B1 KR102736851 B1 KR 102736851B1
Authority
KR
South Korea
Prior art keywords
glucocorticoid
gene signature
glucocorticoids
individual
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207008663A
Other languages
English (en)
Korean (ko)
Other versions
KR20200040872A (ko
Inventor
줄리 카르만
얀후아 후
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20200040872A publication Critical patent/KR20200040872A/ko
Application granted granted Critical
Publication of KR102736851B1 publication Critical patent/KR102736851B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
KR1020207008663A 2017-08-30 2018-08-28 글루코코르티코이드의 생체내 투여에 의해 매개된 약역학적 반응을 모니터링하는 방법 Active KR102736851B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762551839P 2017-08-30 2017-08-30
US62/551,839 2017-08-30
PCT/US2018/048240 WO2019046233A1 (en) 2017-08-30 2018-08-28 METHOD FOR MONITORING PHARMACODYNAMIC RESPONSES MEDIATED BY IN VIVO DELIVERY OF GLUCOCORTICOIDS

Publications (2)

Publication Number Publication Date
KR20200040872A KR20200040872A (ko) 2020-04-20
KR102736851B1 true KR102736851B1 (ko) 2024-11-29

Family

ID=63678673

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207008663A Active KR102736851B1 (ko) 2017-08-30 2018-08-28 글루코코르티코이드의 생체내 투여에 의해 매개된 약역학적 반응을 모니터링하는 방법

Country Status (7)

Country Link
US (1) US11421278B2 (enExample)
EP (1) EP3676402B1 (enExample)
JP (1) JP7288431B2 (enExample)
KR (1) KR102736851B1 (enExample)
CN (1) CN111051534B (enExample)
ES (1) ES2971091T3 (enExample)
WO (1) WO2019046233A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113990486B (zh) * 2021-10-27 2025-08-22 北京博富瑞医学检验实验室有限公司 一种基于aGVHD biomarker的一线糖皮质激素治疗反应预测模型

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005503790A (ja) * 2001-08-17 2005-02-10 インサイト・ゲノミックス・インコーポレイテッド 輸送体及びイオンチャネル
JP2014504272A (ja) * 2010-11-10 2014-02-20 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３特異的結合ドメインによって引き起こされる有害作用の予防

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384736B2 (en) * 2001-09-06 2008-06-10 Decode Genetics Ehf. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
CN1193761C (zh) * 2003-06-25 2005-03-23 暨南大学 一种糖皮质激素的可控释放体系及其制备方法
SE0401032D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new acute glucocorticoid therapy
JP5355890B2 (ja) * 2004-09-09 2013-11-27 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム グルココルチコイドおよびグルココルチコイド誘導体のリポソーム性組成物
WO2013082288A1 (en) * 2011-11-29 2013-06-06 The Regents Of The University Of California Glucorticoid receptor gene nr3c1 methylation in irritable bowel syndrome and other stress disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005503790A (ja) * 2001-08-17 2005-02-10 インサイト・ゲノミックス・インコーポレイテッド 輸送体及びイオンチャネル
JP2014504272A (ja) * 2010-11-10 2014-02-20 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３特異的結合ドメインによって引き起こされる有害作用の予防

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neuropsychopharmacology,2012년, vol.37,p.1455-1464

Also Published As

Publication number Publication date
JP2020532302A (ja) 2020-11-12
EP3676402B1 (en) 2023-12-27
CN111051534A (zh) 2020-04-21
WO2019046233A1 (en) 2019-03-07
EP3676402A1 (en) 2020-07-08
KR20200040872A (ko) 2020-04-20
ES2971091T3 (es) 2024-06-03
CN111051534B (zh) 2025-05-30
JP7288431B2 (ja) 2023-06-07
US11421278B2 (en) 2022-08-23
US20200299770A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
Paugh et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells
Espinosa et al. p53 functions through stress-and promoter-specific recruitment of transcription initiation components before and after DNA damage
Yu et al. T cell–intrinsic function of the noncanonical NF-κB pathway in the regulation of GM-CSF expression and experimental autoimmune encephalomyelitis pathogenesis
US8647822B2 (en) Determining whether a test compound modulates PD-1 activity in activated immune cells using gene expression profiles
Seifuddin et al. Genome-wide Methyl-Seq analysis of blood-brain targets of glucocorticoid exposure
Lucafo et al. Long noncoding RNA GAS5: a novel marker involved in glucocorticoid response
AU2022224759B2 (en) Diagnostic methods
Hu et al. Development of a molecular signature to monitor pharmacodynamic responses mediated by in vivo administration of glucocorticoids
Lenna et al. Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension
Sousa et al. Autologous haematopoietic stem cell transplantation reduces abnormalities in the expression of immune genes in multiple sclerosis
de Sá et al. Clinical and genetic markers associated with tuberculosis, HIV-1 infection, and TB/HIV-immune reconstitution inflammatory syndrome outcomes
Greenough et al. A gene expression signature that correlates with CD8+ T cell expansion in acute EBV infection
CN109996895A (zh) 体外诊断精神障碍的方法和生物标志物
Singh et al. A molecular signature for CD8+ T cells from visceral leishmaniasis patients
Søndergaard et al. Pregnancy-induced changes in microRNA expression in multiple sclerosis
Cuzzoni et al. Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome
Ban et al. Transcript specific regulation of expression influences susceptibility to multiple sclerosis
KR102736851B1 (ko) 글루코코르티코이드의 생체내 투여에 의해 매개된 약역학적 반응을 모니터링하는 방법
Prado et al. Glucocorticoids enhance Th17/Th1 imbalance and signal transducer and activator of transcription 3 expression in systemic lupus erythematosus patients
Sajan et al. Identification of direct downstream targets of Dlx5 during early inner ear development
Fritsch-Stork et al. Expression of ERAP2 and LST1 is increased before start of therapy in rheumatoid arthritis patients with good clinical response to glucocorticoids
Dahm et al. A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women
Rawat et al. Genomics links inflammation with neurocognitive impairment in children living with human immunodeficiency virus type-1
Kolić et al. Expression of LEP, LEPR and PGC1A genes is altered in peripheral blood mononuclear cells of patients with relapsing-remitting multiple sclerosis
Khalyfa et al. Transcription profiling of estrogen target genes in young and old mouse uterus

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200325

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210827

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240109

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20240327

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241115

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241127

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241127

End annual number: 3

Start annual number: 1

PG1601 Publication of registration